Cluster | |||||
1 | 2 | 3 | 4 | 5 | |
Subjects n | 15 | 14 | 30 | 78 | 38 |
Male | 11 (73.3) | 12 (85.7) | 19 (63.3) | 46 (59.0) | 21 (55.3) |
Macroscopic emphysema# | 5 (33.3) | 3 (21.4) | 1 (3.3) | 1 (1.3) | 1 (2.6) |
PEF variability¶ | 6 (40.0) | 4 (28.6) | 4 (13.3) | 7 (9.0) | 8 (21.1) |
Eczema | 7 (46.7) | 5 (35.7) | 15 (50.0) | 29 (37.2) | 19 (50.0) |
Rhinitis | 11 (73.3) | 3 (21.4) | 26 (86.7) | 46 (59.0) | 27 (71.1) |
Hospitalised+ ever | 4 (26.7) | 2 (14.3) | 8 (26.7) | 10 (12.8) | 9 (23.7) |
Hospitalised+ in last year | 1 (6.7) | 0 (0) | 0 (0) | 1 (1.3) | 4 (10.5) |
Inhaled β2-agonist | 8 (53.3) | 4 (28.6) | 13 (43.3) | 22 (28.2) | 13 (34.2) |
Inhaled corticosteroids | 4 (26.7) | 3 (21.4) | 10 (30.3) | 18 (23.1) | 16 (42.1) |
Inhaled antimuscarinic | 0 (0) | 1 (17.1) | 0 (0) | 0 (0) | 1 (2.6) |
Any inhaler | 8 (53.3) | 5 (35.7) | 14 (46.7) | 29 (32.1) | 17 (44.7) |
Age yrs | 64.7±7.6 | 65.5±8.6 | 52.4±14.6 | 56.1±14.5 | 58.2±11.6 |
Eosinophils 109 cells·L−1 | 0.27±0.17 | 0.21±0.19 | 0.22±0.09 | 0.18±0.14 | 0.27±0.16 |
MMEF % pred | 28.6±12.9 | 34.1±13.9 | 58.9±25.1 | 69.6±22.9 | 66.9±24.5 |
sGaw % pred | 46.6±28.9 | 52.3±24.0 | 61.6±22.9 | 77.0±26.2 | 73.3±29.2 |
Maximum PEF variability§ | 22.5±15.0 | 16.8±14.4 | 12.2±8.4 | 10.9±7.0 | 13.9±16.4 |
SGRQ score | 28.0±18.2 | 21.9±16.8 | 12.6±11.9 | 9.9±11.1 | 23.6±18.3 |
Data are presented as mean±sd or n (%), unless otherwise indicated. PEF: peak expiratory flow; MMEF: maximal mid-expiratory flow; % pred: % predicted; sGaw: specific airway conductance; SGRQ: St George’s Respiratory Questionnaire. #: radiological (computed tomography) evidence of definite emphysematous changes; ¶: variability of >20% during 1 week of testing; +: due to respiratory disorder; §: amplitude of mean.